<DOC>
	<DOCNO>NCT01330446</DOCNO>
	<brief_summary>The goal clinical research study learn armodafinil reduce fatigue common symptom patient receive treatment head neck cancer .</brief_summary>
	<brief_title>Single Agent Armodafinil Patient-Reported Fatigue</brief_title>
	<detailed_description>Armodafinil design stimulate central nervous system , may increase wakefulness reduce fatigue . A placebo drug . It look like study drug design treat disease illness . It design compare study drug learn study drug real effect . Study Groups : If find eligible take part study , randomly assign ( flip coin ) 1 2 group . Group 1 take armodafinil . Group 2 take placebo . A placebo substance look like study drug active ingredient . Neither study staff know receive study drug placebo . However , need safety , study staff able find receiving . Study Drug Administration : You take study drug/placebo every day 4 week start morning enrol study . You take study drug/placebo morning full glass ( 8 ounce ) water . You may take study drug/placebo without food . If dose cause upset stomach , take food . If trouble swallow dose study drug/placebo , study staff tell different way take . You give pamphlet information take study drug/placebo . Symptom Questionnaires : Before start take study drug/placebo , follow test procedure perform : Â° You complete 6 questionnaire fatigue , sleepiness , symptom well quality life ability work . These questionnaire take 20 minute complete total . Throughout study , complete 2 symptom questionnaire list 2 time every week study , include Open-label Extension Phase ( describe ) . You may complete questionnaire phone use Interactive Voice Response ( IVR ) system member study staff . Another option complete questionnaire routinely schedule visit outside study . If complete questionnaire phone , study staff IVR system call time convenient . If questionnaire complete IVR system , study staff give information need report symptom use system . If questionnaire complete study staff , she/he ask question record answer paper enter computer . When complete questionnaire second time week , also ask take study drug/placebo instruct asked side effect may . If questionnaire complete IVR system , study staff contact ask take study drug/placebo instruct side effect may . At end Week 4 , complete set 6 questionnaire complete begin study . You also complete questionnaire thought study drug/placebo . You also ask change drug ( prescribe counter ) may take . This take 30 minute . Open-label Extension : At end Week 4 , Group 1 intolerable side effect , able continue take armodafinil additional 4 week . If Group 2 intolerable side effect , give option begin receive armodafinil 4 week . No matter choose , tell whether take study drug placebo first 4 week study . If open-label extension phase , end Week 8 , complete set 6 questionnaire complete begin study . You also complete questionnaire thought study drug/placebo . This take 30 minute . Length Treatment : You receive study drug/placebo either 4 8 week . You take study intolerable side effect occur study doctor think best interest . Follow-Up : After last dose study drug/placebo , continue complete 2 symptom questionnaires another 4 week . The last time complete 2 questionnaire , complete additional 3 questionnaire complete begin study . This investigational study . Armodafinil FDA-approved commercially available treat narcolepsy ( fall asleep unexpected time ) , obstructive sleep apnea , shift work sleep disorder . It also FDA-approved commercially available treat sleepiness patient excessive sleepiness . Its use study investigational . Up 40 patient take part study . Up 25 enrol MD Anderson .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Armodafinil</mesh_term>
	<mesh_term>Modafinil</mesh_term>
	<criteria>1 . Patients treat either definitive postoperative radiation chemoradiation therapy HNC moderate severe level patient report fatigue , 6 week complete planned cancer therapy . Patients rat fatigue level 5 great 0 10 scale followup clinic visit MD Anderson LBJ Hospital . 2 . Male female patient &gt; = 18 year old . 3 . Patients speak English ( due novel research complexity , accrue Englishspeaking patient protocol ) . 4 . Patients must agree discontinue current herbal supplement use , refrain take herbal supplement protocol . 5 . Patients must willing able review understand inform consent document provide write consent . 6 . Women childbearing potential ( woman postmenopausal least 1 year surgically sterile ) must negative urine pregnancy test . 7 . Sexually active male female must agree use effective birth control abstinent duration study period . 8 . Women currently take birth control pills plan start birth control pill must agree additional method birth control ( either abstinence barrier method ) study medication 1 additional month study completion . 1 . Patients rat fatigue level 4 less past 24 hour base fatigue bad item BFI . 2 . Patients clinical evidence active persistent cancer progressive disease complete plan cancer therapy , active recurrent cancer . 3 . Patients potential medical underlying cause fatigue , determine treat physician PI 4 . Patients Hb &lt; 10.5 g/dL within previous 2 week . 5 . Patients untreated uncontrolled hypothyroidism , TSH &gt; ULN free T4 &lt; low level normal within previous 2 week . 6 . Patients underlie cardiac pulmonary disease result dyspnea , hypoxia , hypercapnia . 7 . Patients Karnofsky performance status &lt; 70 8 . Patients le 18 year old 9 . Patients enrol receive active treatment symptom intervention trial treatment phase another clinical trial 10 . Patients preexist psychosis bipolar disorder 11 . Patients preexist renal impairment , evidence serum creatinine &gt; ULN recent blood work , do least within previous 2 week . 12 . Patients preexist cirrhosis hepatic impairment abnormal liver function test evidence total bilirubin &gt; 1.5 x ULN 2 time upper limit normal alkaline phosphatase ( ALP ) , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) recent blood work , do least within previous 2 week . 13 . Patients preexist Tourette 's syndrome 14 . Patients used monoamine oxidase ( MAO inhibitor ) within past 14 day 15 . Patients undergo abrupt discontinuation ethanol sedative ( include benzodiazepine ) 16 . Patients currently take , take within previous 1 month , armodafinil , modafinil , amphetamine , methylphenidate 17 . Patients anticoagulant ( i.e . warfarin , coumadin , heparin ) clopidogrel 18 . Patients history clinically significant cutaneous drug reaction , history clinically significant hypersensitivity reaction , include multiple allergy drug reaction 19 . Patients history angina cardiac ischemia , recent history myocardial infarction ( within past 1 year ) leave ventricular hypertrophy , patient mitral valve prolapse 20 . Patients uncontrolled hypertension tachycardia , determine treat physician 21 . Patients pregnant , breastfeeding , plan become pregnant study period 1 month stop study drug . 22 . Female patient currently birth control pill primary mean contraception , willing seek additional effective method contraception ( barrier method ) study period 1 month stop study drug . 23 . Patients history CNS stimulant abuse , methylphenidate , dextroamphetamine , modafinil . 24 . Patients major depressive disorder severe depression ( score 13 great BDI Fast Screen ( BDIFS ) . If case , notify treat physician appropriate management referral . 25 . Patients current history suicidal ideation . 26 . Patients currently take midazolam , cyclosporine , ethinyl estradiol , triazolam 27 . Patients currently take carbamazepine , phenobarbital , rifampin , aminoglutethimide , nafcillin , nevirapine , phenytoin , azole antifungal , clarithromycin , diclofenac , doxycycline , erythromycin , imatinib , isoniazid , nefazodone , nicardipine , propofol , protease inhibitor , quinidine , telithromycin , verapamil 28 . Patients currently take omeprazole , diazepam , propanolol , chlomipramine ( tricyclic antidepressant ) , citalopram , methsuximide , sertraline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Head Neck Cancer</keyword>
	<keyword>HNC</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Patient-Reported Fatigue</keyword>
	<keyword>Fatigue-Symptom Intervention</keyword>
	<keyword>Postoperative Radiation Therapy</keyword>
	<keyword>Postoperative Chemoradiation Therapy</keyword>
	<keyword>Armodafinil</keyword>
	<keyword>Nuvigil</keyword>
	<keyword>Placebo</keyword>
	<keyword>Sugar Pill</keyword>
	<keyword>Questionnaires</keyword>
	<keyword>Surveys</keyword>
</DOC>